SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Catalyst Pharmaceutical Partners, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of December 24, 2013 -- CPRX

NEW YORK, NY--(Marketwired - Dec 12, 2013) - Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of Florida on behalf of investors who purchased Catalyst Pharmaceutical Partners, Inc. ("Catalyst Pharmaceutical" or the "Company") (NASDAQ: CPRX) common stock between October 31, 2012 and October 18, 2013.

For more information, click here: http://zlk.9nl.com/catalyst-pharmaceutical-partners-cprx/.

The Complaint alleges that the Company made materially false and misleading statements and/or failed to disclose materially adverse facts during the Class Period. In particular it is alleged that Catalyst Pharmaceutical failed to disclose that one of its competitors has already been manufacturing a drug biologically equivalent to the Company's drug Firedapse, and that this competitor was providing the drugs to patients to treat Lambert-Eaton Myasthenic Syndrome (LEMS) free of charge, through a compassionate use program.

If you suffered a loss in Catalyst you have until December 24, 2013 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/catalyst-pharmaceutical-partners-cprx/. 

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut, and Washington D.C. The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.